scholarly journals The German Breast Group – Healing Through Innovation, Competence and Partnership

2009 ◽  
Vol 05 (01) ◽  
pp. 41
Author(s):  
Mattea Linder ◽  
Sibylle Loibl ◽  
Gunter von Minckwitz ◽  
◽  
◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Study Group ◽  
Cancer Study ◽  
Cancer Study Group ◽  
Breast Cancer Study ◽  
Innovation Competence ◽  
Breast Group ◽  
German Breast Group

The German Breast Group (GBG) is the leading breast cancer study group in Germany, conducting clinical trials in the adjuvant, neoadjuvant, preventative and palliative settings. One focus of the GBG is neoadjuvant studies, which have a long and successful history in Germany. The aim of neoadjuvant studies is to improve operability and to gain more information about the tumour itself in terms of the chemotherapy (invivo) as well as regarding the biology in general. However, preventative, palliative and adjuvant studies are also important components of the GBG. This article is an overview of the structure and working practice of the GBG and gives a sample of trials currently being led by the GBG.

scholarly journals Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V

2016 ◽  
Vol 34 (9) ◽  
pp. 927-935 ◽  
Author(s):  
Marco Colleoni ◽  
Zhuoxin Sun ◽  
Karen N. Price ◽  
Per Karlsson ◽  
John F. Forbes ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Treatment Strategies ◽  
Disease Free Survival ◽  
Entire Group ◽  
Study Group ◽  
Cancer Study ◽  
Cancer Study Group ◽  
Breast Cancer Study ◽  
Er Positive

Purpose Predicting the pattern of recurrence can aid in the development of targeted surveillance and treatment strategies. We identified patient populations that remain at risk for an event at a median follow-up of 24 years from the diagnosis of operable breast cancer. Patients and Methods International Breast Cancer Study Group clinical trials I to V randomly assigned 4,105 patients between 1978 and 1985. Annualized hazards were estimated for breast cancer–free interval (primary end point), disease-free survival, and overall survival. Results For the entire group, the annualized hazard of recurrence was highest during the first 5 years (10.4%), with a peak between years 1 and 2 (15.2%). During the first 5 years, patients with estrogen receptor (ER) – positive disease had a lower annualized hazard compared with those with ER-negative disease (9.9% v 11.5%; P = .01). However, beyond 5 years, patients with ER-positive disease had higher hazards (5 to 10 years: 5.4% v 3.3%; 10 to 15 years: 2.9% v 1.3%; 15 to 20 years: 2.8% v 1.2%; and 20 to 25 years: 1.3% v 1.4%; P < .001). Among patients with ER-positive disease, annualized hazards of recurrence remained elevated and fairly stable beyond 10 years, even for those with no axillary involvement (2.0%, 2.1%, and 1.1% for years 10 to 15, 15 to 20, and 20 to 25, respectively) and for those with one to three positive nodes (3.0%, 3.5%, and 1.5%, respectively). Conclusion Patients with ER-positive breast cancer maintain a significant recurrence rate during extended follow up. Strategies for follow up and treatments to prevent recurrences may be most efficiently applied and studied in patients with ER-positive disease followed for a long period of time.

Sign in / Sign up

Export Citation Format

Share Document